99815-16-4

Usage

Uses

Used in Pharmaceutical Industry:
3,4-Bis(tert-butyldiMethylsilyloxy)benzaldehyde is used as a reactant for the preparation of dihydroxy stilbene derivatives, which serve as PTP1B inhibitors. PTP1B inhibitors are of interest in the development of treatments for type 2 diabetes and obesity, as they help regulate insulin signaling and glucose homeostasis.

Upstream product

• 18162-48-6 tert-butyldimethylsilyl chloride 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 121-33-5 vanillin 

Downstream Products

• 109032-32-8 {[4-(2,2-dibromovinyl)-1,2-phenylene]bis-(oxy)}bis(tert-butyldimethylsilane) 
• 914954-92-0 (+/-)-1-[(3',4'-bis-(tert-butyldimethylsilanoxy)phenyl)]prop-2-en-1-ol 
• 1036243-79-4 [3,4-bis(tert-butyl-dimethyl-silanyloxy)-phenyl]methanol 
• 1260116-24-2 (E)-(5-(4-nitrostyryl)-1,3-phenylene)bis(oxy)bis(tert-butyldimethylsilane) 
• 1260116-27-5 (E)-4-(3,4-bis(tert-butyldimethylsilyloxy)styryl)benzenamine 
• 1260116-06-0 (E)-5-(4-aminostyryl)benzene-1,3-diol 
• 1260116-07-1 C₁₅H₁₅NO₂ 
• 1260116-08-2 C₁₆H₁₅NO₃ 
• 1260116-09-3 (E)-1-(4-(3,4-dihydroxystyryl)phenyl)-3-phenylurea 
• 1260116-10-6 (E)-1-(4-(3,4-dihydroxystyryl)phenyl)-3-(4-methoxyphenyl)urea 
• 1260116-11-7 (E)-1-(4-aminophenyl)-3-(4-(3,4-dihydroxystyryl)phenyl)urea 
• 1260116-12-8 (E)-1-(4-(3,4-dihydroxystyryl)phenyl)-3-p-tolylurea 
• 1260116-13-9 (E)-1-(4-(3,4-dihydroxystyryl)phenyl)-3-(4-trifluoromethylphenyl) 
• 1260116-14-0 (E)-1-(4-(3,4-dihydroxystyryl)phenyl)-3-(4-fluorophenyl)urea 

Relevant academic research and scientific papers

Demonstrating the role of anchoring functionality in interfacial electron transfer dynamics in the newly synthesized BODIPY-TiO2 nanostructure composite

New BODIPY derivatives (dyes 1 and 2) with either catechol or resorcinol functionality, respectively, for anchoring to nanostructured (NS) TiO2 surfaces were synthesized. Extended conjugation at one of the two pyrrole rings at the C3 position helped us to achieve the desired control in tuning the optical and redox properties of the BODIPY based dye molecules. Relative emission quantum yields (Φem1 = ～52 ± 2% and Φem2 = 54 ± 2%) were found to be much higher in a polar aprotic solvent (acetonitrile) and substantially lower for dye 1 in a polar protic solvent. Steady state optical absorption studies revealed the formation of a strong charge transfer complex between dye 1 and NS-TiO2, while this interaction was much weaker for dye 2. Transient absorption studies were carried out for 1/NS-TiO2 and 2/NS-TiO2 systems following excitation with a laser source of 400 nm to understand the charge transfer dynamics. The results of the transient absorption spectral studies helped us to elucidate the role of anchoring functionality in influencing the dynamics of interfacial electron transfer and charge recombination processes on an ultrafast timescale.

Synthesis, evaluation and molecular modelling of piceatannol analogues as arginase inhibitors

Arginase is involved in a wide range of pathologies including cardiovascular diseases and infectious diseases whilst it is also a promising target to improve cancer immunotherapy. To date, only a limited number of inhibitors of arginase have been reported. Natural polyphenols, among them piceatannol, are moderate inhibitors of arginase. Herein, we report our efforts to investigate catechol binding by quantum chemistry and generate analogues of piceatannol. In this work, we synthesized a novel series of amino-polyphenols which were then evaluated as arginase inhibitors. Their structure-activity relationships were elucidated by deep quantum chemistry modelling. 4-((3,4-Dihydroxybenzyl)amino)benzene-1,2-diol3tdisplays a mixed inhibition activity on bovine and human arginase I with IC50(Ki) values of 76 (82) μM and 89 μM, respectively.

Discovery and Development of S6821 and S7958 as Potent TAS2R8 Antagonists

In humans, bitter taste is mediated by 25 TAS2Rs. Many compounds, including certain active pharmaceutical ingredients, excipients, and nutraceuticals, impart their bitter taste (or in part) through TAS2R8 activation. However, effective TAS2R8 blockers that can either suppress or reduce the bitterness of these compounds have not been described. We are hereby reporting a series of novel 3-(pyrazol-4-yl) imidazolidine-2,4-diones as potent and selective TAS2R8 antagonists. In human sensory tests, S6821 and S7958, two of the most potent analogues from the series, demonstrated efficacy in blocking TAS2R8-mediated bitterness and were selected for development. Following data evaluation by expert panels of a number of national and multinational regulatory bodies, including the US, the EU, and Japan, S6821 and S7958 were approved as safe under conditions of intended use as bitter taste blockers.

Design, synthesis, and evaluation of curcumin derivatives as Nrf2 activators and cytoprotectors against oxidative death

Activation of nuclear factor erythroid-2-related factor 2 (Nrf2) has been proven to be an effective means to prevent the development of cancer, and natural curcumin stands out as a potent Nrf2 activator and cancer chemopreventive agent. In this study, we synthesized a series of curcumin analogs by introducing the geminal dimethyl substituents on the active methylene group to find more potent Nrf2 activators and cytoprotectors against oxidative death. The geminally dimethylated and catechol-type curcumin analog (compound 3) was identified as a promising lead molecule in terms of its increased stability and cytoprotective activity against the tert-butyl hydroperoxide (t-BHP)-induced death of HepG2 cells. Mechanism studies indicate that its cytoprotective effects are mediated by activating the Nrf2 signaling pathway in the Michael acceptor- and catechol-dependent manners. Additionally, we verified by using copper and iron ion chelators that the two metal ion-mediated oxidations of compound 3 to its corresponding electrophilic o-quinone, contribute significantly to its Nrf2-dependent cytoprotection. This work provides an example of successfully designing natural curcumin-directed Nrf2 activators by a stability-increasing and proelectrophilic strategy.

Resveratrol derivative containing fluorine group, and preparation method and application

The invention belongs to the technical field of medicines and discloses a resveratrol derivative containing a fluorine group, and a preparation method and an application. The resveratrol derivative has the structural characteristics as shown in a general

The design, synthesis and biological evaluation of pro-EGCG derivatives as novel anti-vitiligo agents

With the aim of overcoming the instability and poor membrane permeability of epigallocatechin-3-gallate (EGCG), a series of prodrugs of EGCG and its derivatives (pro-EGCGs) were designed and synthesized, and their protective effect on melanocytes against

Novel multifunctional dopamine D2/D3receptors agonists with potential neuroprotection and anti-alpha synuclein protein aggregation properties

Our ongoing drug development endeavor to design compounds for symptomatic and neuroprotective treatment of Parkinson's disease (PD) led us to carry out a structure activity relationship study based on dopamine agonists pramipexole and 5-OHDPAT. Our goal was to incorporate structural elements in these agonists in a way to preserve their agonist activity while producing inhibitory activity against aggregation of α-synuclein protein. In our design we appended various catechol and related phenol derivatives to the parent agonists via different linker lengths. Structural optimization led to development of several potent agonists among which (?)-8a, (?)-14 and (?)-20 exhibited potent neuroprotective properties in a cellular PD model involving neurotoxin 6-OHDA. The lead compounds (?)-8a and (?)-14 were able to modulate aggregation of α-synuclein protein efficiently. Finally, in an in vivo PD animal model, compound (?)-8a exhibited efficacious anti-parkinsonian effect.

Synthesis, characterization, and antioxidant activity of Zn2+ and Cu2+ coordinated polyhydroxychalcone complexes

Four new metal complexes [Cu(ISO)2], [Cu(BUT)2] and [Zn(ISO)2], [Zn(BUT)2] of the polyhydroxychalcones (isoliquiritigenin and butein) are synthesized, structurally characterized and their antioxidant activity is investigated. The formation of the complexes [Cu(ISO)2] and [Zn(ISO)2] is followed by Job’s plot using NMR titration. The resulting compounds are characterized by mass spectrometry, IR spectroscopy, and elemental analysis. Studies on the radical scavenging activity are performed using DPPH as substrate. The results showed that the antioxidant activities of isoliquiritigenin and butein are enhanced after binding to copper or zinc. Graphical abstract: [Figure not available: see fulltext.]

Toward chelerythrine optimization: Analogues designed by molecular simplification exhibit selective growth inhibition in non-small-cell lung cancer cells

A series of novel chelerythrine analogues was designed and synthesized. Antitumor activity was evaluated against A549, NCI-H1299, NCI-H292, and NCI-H460 non-small-cell lung cancer (NSCLC) cell lines in vitro. The selectivity of the most active analogues a

A PROCESS FOR THE PREPARATION PUERARIAFURAN

The present invention relates to a chemical method for producing puerariafuran, which is separated from Pueraria thunbergiana having various physiological activities, and derivatives thereof. The chemical method for producing puerariafuran and derivatives